If potent and specific drug-like inhibitors of TLS polymerases can be further developed they may represent a novel therapeutic strategy for a majority subgroup of TNBCs and potentially other tumour sites with clearly identifiable HORMAD1 expression. This evidence concerns the gene HORMAD1 and neoplasm.